
Sign up to save your podcasts
Or


In the rush to develop a vaccine or treatment for Covid-19, drug companies are fast-tracking clinical trials. But those trials have a major diversity problem. Participants in major drug trials range from 70 percent to 89 percent white. This is a big problem, considering it’s a disease that disproportionately affects people of color. Kristen V. Brown reports that failing to account for minority groups could potentially impact how well a drug eventually works for those that the virus has harmed the most.
See omnystudio.com/listener for privacy information.
By Bloomberg3.7
805805 ratings
In the rush to develop a vaccine or treatment for Covid-19, drug companies are fast-tracking clinical trials. But those trials have a major diversity problem. Participants in major drug trials range from 70 percent to 89 percent white. This is a big problem, considering it’s a disease that disproportionately affects people of color. Kristen V. Brown reports that failing to account for minority groups could potentially impact how well a drug eventually works for those that the virus has harmed the most.
See omnystudio.com/listener for privacy information.

78,717 Listeners

32,240 Listeners

6,976 Listeners

28,978 Listeners

16,309 Listeners

2,679 Listeners

408 Listeners

2,171 Listeners

1,994 Listeners

437 Listeners

12,118 Listeners

17,595 Listeners

971 Listeners

113,515 Listeners

195 Listeners

30 Listeners

10,242 Listeners

4 Listeners

58 Listeners

233 Listeners

228 Listeners

69 Listeners

80 Listeners

86 Listeners

397 Listeners

21 Listeners

12 Listeners

8 Listeners

2 Listeners

123 Listeners

1,171 Listeners

183 Listeners